Orlewska Ewa, Mierzejewski Piotr
Centre for Pharmacoeconomics, Warsaw, Poland.
Value Health. 2004 Jan-Feb;7(1):1-10. doi: 10.1111/j.1524-4733.2004.71257.x.
Financial analysis (budget impact analysis, BIA) is increasingly required by decision-makers to ascertain the macroeconomic consequences of new product reimbursement in addition to proof of cost-effectiveness. Poland is in the process of drafting country-specific guidelines for BIA, positioned as complementary to economic evaluation in decision-making
The aim of this article is to present the Polish project and compare it with currently available guidance.
A checklist was developed that focuses on issues that are unique to BIA. An analysis of the differences between different national guidelines and their Polish counterparts was subsequently undertaken.
The Polish project of BIA guidelines is composed of two sections. The first section presents the objective, the use of BIA, the responsibility for the preparation, and the target audience. The second section presents important methodological aspects that researchers should keep in mind when carrying out BIA. In comparison to existing guidance the Polish project appears to be more detailed. It includes more precise recommendations on perspective, time horizon, and reliability of data sources; reporting of results; rates of adoption of new therapies; and the probability of redeploying resources.
Although there is an increased demand for BIA, there is only limited guidance on how such studies should be undertaken. It is hoped that the Polish guidelines can contribute to the development of such analyses and deliver benefit for Polish health-care decision-makers and beyond.
决策者越来越需要进行财务分析(预算影响分析,BIA),以确定新产品报销的宏观经济后果,此外还要证明其成本效益。波兰正在起草针对特定国家的BIA指南,该指南被定位为决策中经济评估的补充。
本文旨在介绍波兰的项目,并将其与当前可用的指南进行比较。
制定了一份清单,重点关注BIA特有的问题。随后对不同国家指南与其波兰对应指南之间的差异进行了分析。
波兰的BIA指南项目由两部分组成。第一部分介绍了目标、BIA的用途、编制责任和目标受众。第二部分介绍了研究人员在进行BIA时应牢记的重要方法学方面。与现有指南相比,波兰项目似乎更详细。它包括关于视角、时间范围和数据源可靠性、结果报告、新疗法采用率以及资源重新配置可能性的更精确建议。
尽管对BIA的需求不断增加,但关于如何开展此类研究的指导却很有限。希望波兰的指南能够促进此类分析的发展,并为波兰及其他国家的医疗保健决策者带来益处。